Hyperfine Strengthens Leadership with AI Experts to Advance Portable MRI Technology

Hyperfine, Inc. (Nasdaq: HYPR), a pioneering health technology company, has bolstered its leadership team with the appointment of Rob Fasciano, PhD, as Chief Regulatory and Quality Officer, and Rafael O’Halloran, PhD, as Vice President of Technology. Both executives bring extensive experience in the medical technology sector, which will significantly enhance Hyperfine's capabilities as it scales the commercialization of its next-generation Swoop® system with the newly FDA-cleared Optive AI™ software. Dr. Rob Fasciano, with over 25 years of experience in regulatory affairs, quality systems, and R&D, joins Hyperfine from companies like Abiomed, Johnson & Johnson, Orchestra BioMed, and Impulse Dynamics. His educational background includes a PhD from Johns Hopkins University, an MBA from Purdue University, and advanced degrees from Boston University and Dartmouth College. Dr. Fasciano will play a crucial role in ensuring the Swoop® system and its associated software meet rigorous regulatory standards, facilitating global market entry and expansion. Dr. Rafael O’Halloran, with two decades of expertise in MRI physics and innovation in sequence development and image reconstruction, was previously an Assistant Professor of Radiology at the Mount Sinai School of Medicine. At Mount Sinai, he focused on using diffusion-weighted imaging in neuromodulation and the study of psychiatric disorders. He also served as a research associate at Stanford University. Dr. O’Halloran holds a PhD in medical physics from the University of Wisconsin-Madison and a BS in physics from Louisiana State University. In his new role at Hyperfine, he will lead the development of advanced imaging technologies and software enhancements, building on the company's existing achievements. Maria Sainz, President and CEO of Hyperfine, expressed her enthusiasm about the appointments, stating that they strengthen the company's ability to innovate and scale commercially. "Technology innovation is at the core of our mission and central to accelerating global adoption of the Swoop® system. Rob’s expertise in regulatory compliance and quality assurance will be invaluable as we prepare to launch globally. Rafael’s leadership in AI-driven image processing has been crucial in raising our imaging standards," she said. The Swoop® Portable MR Imaging® System is the first FDA-cleared, portable, ultra-low-field MRI device designed for brain imaging at various points of professional care. It provides imaging when full diagnostic examinations are not practical and is interpreted by trained physicians to assist in diagnosis. The Swoop® system is particularly notable for its portability and accessibility, making it a valuable tool for delivering diagnostic imaging across different healthcare settings, including emergency departments, clinics, and remote locations. The next-generation model, enhanced with Optive AI™ software, is expected to improve image quality and usability, thus broadening its clinical applications and user base. This advanced software leverages artificial intelligence to optimize image acquisition and analysis, offering a more streamlined and effective diagnostic process. Founded by Dr. Jonathan Rothberg in a technology-focused incubator called 4Catalyzer, Hyperfine, Inc. is committed to transforming brain health through accessible and reliable imaging solutions. The company's mission is to revolutionize patient care globally by providing cost-effective, high-quality diagnostic tools that can be used at multiple points of care. The development of the Swoop® system involved a dedicated team of scientists, engineers, and physicists passionate about redefining brain imaging methods. These strategic hires come at a crucial time for Hyperfine, as the company prepares to roll out the next-generation Swoop® scanner internationally. Dr. Fasciano's and Dr. O’Halloran's contributions are expected to accelerate the company's growth and enhance its competitive edge in the rapidly evolving medical imaging market. Industry insiders view these appointments as a strong move by Hyperfine to solidify its position in the medical technology sector. The addition of such seasoned professionals, especially in critical areas like regulatory compliance and imaging technology, is seen as essential for the company's continued success and expansion. Hyperfine, known for its innovative approach to healthcare technology, is poised to lead the way in making portable MRI systems a standard part of global brain health care. Hyperfine, Inc. (Nasdaq: HYPR) is a leader in accessible and affordable MRI technology. Founded to address the challenges of traditional MRI systems, Hyperfine aims to make brain imaging available and practical for a wide range of healthcare settings. For more information, visit HyperfineMRI.com.